Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company develops therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.
Frequently asked questions
What sector does Statera Biopharma Inc (STAB) operate in?
Statera Biopharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Statera Biopharma Inc (STAB) current stock price?
As of the latest data, Statera Biopharma Inc stock price is $0.00, with a previous close of $0.00.
What is Statera Biopharma Inc (STAB) current market capitalization?
Statera Biopharma Inc market cap is approximately 7.14 thousand.
What is Statera Biopharma Inc (STAB) Earnings Per Share (EPS)?
The trailing EPS is -$0.39.
Does Statera Biopharma Inc (STAB) pay dividends?
No. Statera Biopharma Inc does not pay a dividend.
What is Statera Biopharma Inc (STAB) beta (volatility) score?
Statera Biopharma Inc has a beta of 195.969, indicating very high volatility compared to the market.